Bioactive compounds from Okinawan marine cyanobacteria

Toshiaki Teruya, Osamu Ohno, Kiyotake Suenaga

研究成果: Chapter

抄録

Natural products, especially those from terrestrial plants and microbes, have been the most productive source of drug molecules over the years, and pharmacologically active compounds from plants and microbes continue to play an important role in developing new investigational drugs (Butler 2008; Newman and Cragg 2007). However, much attention has recently been given to marine organisms due to their remarkable biological activities (Molinski et al. 2009). In particular, cyanobacteria are prolific producers of biologically active compounds (Gerwick, Tan, and Sitachitta 2001). Cyanobacteria have been recognized as a source of pharmaceutical lead compounds (Tan 2007), for example, TZT-1027, a synthetic dolastatin 10 analog, is currently being evaluated in phase II clinical trials in the United States (Yamamoto et al. 2009). Dolastatin 10 was originally isolated from the sea hare Dolabella auricularia and has been subsequently isolated from marine cyanobacterium (Luesch et al. 2001; Pettit et al. 1987). Cryptophycin-309 and cryptophycin-249, which are derivatives of the terrestrial cyanobacterial peptide cryptophycin-1, have undergone preclinical efficacy studies (Liang et al. 2005).

本文言語English
ホスト出版物のタイトルMarine Pharmacognosy
ホスト出版物のサブタイトルTrends and Applications
出版社CRC Press
ページ21-25
ページ数5
ISBN(電子版)9781439892305
ISBN(印刷版)9781439892299
DOI
出版ステータスPublished - 2012 1 1

ASJC Scopus subject areas

  • 医学(全般)
  • 薬理学、毒性学および薬学(全般)
  • 農業および生物科学(全般)
  • 化学 (全般)

フィンガープリント

「Bioactive compounds from Okinawan marine cyanobacteria」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル